1. Review strategies to assess individualized patient characteristics and disease prognosis to determine the role of CD20 in treatment planning 2. Develop treatment plans to delay disability and progression in patients with RMS 3. Review and analyze clinical trial data for CD20 therapeutics to manage patients with RMS
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Pricing
100% of listed courses are free
11 of 11 courses listed here are free.
Collected from the provider’s public pages · source
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Enduring / On-demand
- Credit · Up to 0.75 credits
- Commercial Support
-
ReleasedJun 25, 2026
-
Last day to claim creditJun 25, 2027 9 months left
-
AcademicCME, LLC The Evolving Role of High Efficacy, Anti-CD40 Therapeutics for Relapsing Multiple Sclerosis
-
AcademicCME, LLC Review of Biosimilar Therapeutics for Patients with Relapsing Multiple Sclerosis
-
AcademicCME, LLC Re engineering B Cell Signaling in Sjögren s Disease: BAFF/APRIL Blockade as a New Path to Durable Disease Control
